<DOC>
	<DOCNO>NCT01716481</DOCNO>
	<brief_summary>The objective study test hypothesis ischemic stroke patient moderate severe persistent neurologic deficit well outcomes intravenous transplantation autologous mesenchymal stem cell ( MSCs ) expand autologous serum obtain acute phase stroke patient receive standard treatment .</brief_summary>
	<brief_title>The STem Cell Application Researches Trials In NeuroloGy-2 ( STARTING-2 ) Study</brief_title>
	<detailed_description>In study , use autologous 'ischemic ' serum obtain early time point possible ( immediate randomization ) purpose ischemic preconditioning . We recently conduct preclinical study effect ischemic precondition MSC function . We evaluate characteristic rat MSCs culture fetal bovine serum ( FBS ) serum obtain rat stroke model . Compared FBS , use serum obtain rat stroke model result rapid expansion MSCs , reduce cell preparation time increase G2/M phase , decrease cell death/senescence , increase trophic factor secretion , increase migration capacity .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>1 . Men woman ( woman must nonchild bear potential ) , age 3075 yr . 2 . Have stroke observe within 90 day onset symptom 3 . Radiologically 1 . Relevant lesion within middle cerebral artery territory ( MCA ) assess use diffusionweighted imaging ( DWI ) . 2 . The maximum diameter stroke region dimension must ≥15 mm . 3 . Not involve half ipsilateral periventricular zone 4 . Clinically ( National Institutes Health stroke scale , NIHSS ) 1 . Moderateto severe persistent neurologic deficit ( NIHSS 621 inclusive ) 2 . New onset extremity paresis affect side , define score 24 NIHSS Motor Arm ( item 5 ) Leg ( item 6 ) question . 3 . Must alert drowsy easily arousable define score 01 NIHSS Level Consciousness question ( item 1 ) . 4 . `` Slow recovery '' define Change NIHSS ≤1 point/3 day 5 . Willingness 1 . Reasonable likelihood receive standard physical , occupational speech rehabilitation therapy indicate post stroke deficit . 2 . Able participate evaluation process point accurate assessment . 3 . Willing able comply schedule visit , lifestyle guideline , treatment plan , laboratory test , study procedure . 4 . Evidence personally sign date informed consent document . 1 . Presence significant disability prior current stroke . Significant disability define prestroke modify Rankin score 2 . 2 . Have stroke either 1. lacunar infarction 2 . Hematologic cause stroke 3 . Recurrent progressive stroke within 1 week time screen . 3 . Hematologic disorder bone marrow suppression . 4 . Have severe medical illness 1 . Severe heart failure 2 . Severe febrile illness 3 . Hepatic renal dysfunction 4 . Active cancer 5 . Any evidence chronic comorbid condition unstable acute systemic illness , opinion investigator , could shorten subject 's survival limit ability complete study . 5 . Presence human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , syphilis admission blood test 6 . Presence depression active adequately control interfere major activity daily live immediately prior current stroke . 7 . Presence dementia prior current stroke likely confound clinical evaluation . 8 . Pregnant female determine positive urine human chorionic gonadotropin ( hCG ) test lactating female . 9 . Subjects consider unwilling unable comply procedure study visit schedule outline protocol 10 . Subjects unwilling undergo bone marrow aspiration</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Neurogenesis</keyword>
</DOC>